Progression-free Survival 96% in CLL With Ibrutinib Medscape Jennifer Brown, MD, assistant professor in the Department of Medicine at Harvard Medical School in Cambridge, Massachusetts, presented interim data on ibrutinib in combination with bendamustine and rituximab (Rituxan). Patients received ibrutinib 420 ... |
